We are live on ! Find out more
FO

FT Options Portfolio holdings

AUM $66.4M
1-Year Est. Return 18.48%
This Fund
S&P 500
This Quarter Est. Return
+8.72%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$58.1M
AUM Growth
-$17.9M
Cap. Flow
-$4.42M
Cap. Flow %
-7.61%
Top 10 Hldgs %
43.93%
Holding
340
New
63
Increased
59
Reduced
56
Closed
151

Top Buys

1
CLVS
Clovis Oncology, Inc.
CLVS
+$2.31M
2
AMGN icon
Amgen
AMGN
+$1.97M
3
IBB icon
iShares Biotechnology ETF
IBB
+$1.79M
4
TSRO
TESARO, Inc.
TSRO
+$1.56M
5
CLX icon
Clorox
CLX
+$1.3M

Top Sells

1
ABT icon
Abbott
ABT
+$5.02M
2
AKBA icon
Akebia Therapeutics
AKBA
+$3.63M
3
FL
Foot Locker
FL
+$2.12M
4
GIS icon
General Mills
GIS
+$2.03M
5
LULU icon
lululemon athletica
LULU
+$1.38M

Sector Composition

1 Healthcare 37.51%
2 Consumer Staples 17.11%
3 Consumer Discretionary 2.69%
4 Communication Services 1.36%
5 Materials 1.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KITE
26
CALL
DELISTED
Kite Pharma, Inc.
KITE
$604K 1.04%
25,300
-56,400
-69% -$4.6M
PBYI icon
27
CALL
Puma Biotechnology
PBYI
$428M
$585K 1.01%
+20,900
New +$1.17M
SRPT icon
28
Sarepta Therapeutics
SRPT
$1.82B
$539K 0.93%
15,993
+9,617
+151% +$313K
DIS icon
29
Walt Disney
DIS
$173B
$531K 0.91%
5,000
-3,449
-41% -$378K
CASC
30
DELISTED
Cascadian Therapeutics, Inc.
CASC
$473K 0.81%
127,429
-16,000
-11% -$63.5K
MNK
31
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$448K 0.77%
+10,000
New +$439K
SCYX icon
32
SCYNEXIS
SCYX
$44.5M
$432K 0.74%
3,015
+716
+31% +$119K
PF
33
DELISTED
Pinnacle Foods, Inc.
PF
$422K 0.73%
+7,100
New +$424K
ABT icon
34
CALL
Abbott
ABT
$172B
$417K 0.72%
26,500
– –
CMRX
35
DELISTED
Chimerix, Inc.
CMRX
$410K 0.71%
75,239
– –
INCY icon
36
CALL
Incyte
INCY
$23.3B
$409K 0.7%
30,700
+10,000
+48% +$1.27M
PTLA
37
CALL
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$395K 0.68%
+46,100
New +$1.85M
HAIN icon
38
Hain Celestial
HAIN
$52.5M
$388K 0.67%
10,000
+2,966
+42% +$107K
COST icon
39
Costco
COST
$419B
$368K 0.63%
+2,300
New +$396K
REGN icon
40
Regeneron Pharmaceuticals
REGN
$71.2B
$324K 0.56%
659
+159
+32% +$69.6K
XBI icon
41
State Street SPDR S&P Biotech ETF
XBI
$10.4B
$320K 0.55%
+4,150
New +$294K
INSM icon
42
Insmed
INSM
$23.3B
$308K 0.53%
17,958
+9,483
+112% +$162K
DVAX
43
DELISTED
Dynavax Technologies
DVAX
$297K 0.51%
+30,795
New +$200K
MDCO
44
PUT
DELISTED
Medicines Co
MDCO
$295K 0.51%
17,000
+4,000
+31% +$178K
BMY icon
45
CALL
Bristol-Myers Squibb
BMY
$124B
$290K 0.5%
56,500
+21,900
+63% +$1.19M
REGN icon
46
CALL
Regeneron Pharmaceuticals
REGN
$71.2B
$288K 0.5%
5,000
+2,500
+100% +$1.09M
RCKT icon
47
Rocket Pharmaceuticals
RCKT
$372M
$285K 0.49%
37,500
-81,941
-69% -$611K
FOLD
48
CALL
DELISTED
Amicus Therapeutics
FOLD
$262K 0.45%
84,300
+2,500
+3% +$20.1K
QURE icon
49
uniQure
QURE
$2.71B
$260K 0.45%
41,934
-23,124
-36% -$125K
DVAX
50
CALL
DELISTED
Dynavax Technologies
DVAX
$247K 0.43%
69,700
-26,900
-28% -$175K
1
2
3 4 5

Similar funds

MC
Micawber Capital Seattle, Washington $62.9M AUM 20.32% 1-Year Est. Return
FIM
Friedberg Investment Management Houston, Texas $61.9M AUM 20.07% 1-Year Est. Return
TLIC
Thai Life Insurance Company Bangkok, Thailand $71M AUM 20.14% 1-Year Est. Return
MKCM
Mount Kellett Capital Management New York $61M AUM 12.22% 1-Year Est. Return
ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
MFM
Marianas Fund Management New York $58.1M AUM 10.84% 1-Year Est. Return
VE
Vega Energy New York $75.5M AUM 15.36% 1-Year Est. Return
GFWEV
G.F.W. Energy VIII Irving, Texas $76.3M AUM 11.41% 1-Year Est. Return

FT Options's Q2 2017 Portfolio in Review

As of Q2 2017, FT Options held 340 positions worth $58.1M, down 24% from $76M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

FT Options withdrew a net $4.42M in Q2 2017, closing 151 positions and reducing 56 holdings. Its most notable exit was Foot Locker, an estimated $2.12M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 38% of assets, up from 35% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

Against the trend, FT Options opened a new position in Amgen worth $2.08M.

  • FT Options's largest Q2 2017 buy was Amgen: 12,082 shares worth $2.08M.
  • FT Options added most to Clovis Oncology, Inc. in Q2 2017, an estimated $2.31M increase.
  • FT Options's biggest Q2 2017 reduction was Abbott, cutting an estimated $5.02M.
  • FT Options fully exited Foot Locker in Q2 2017, selling an estimated $2.12M.
  • FT Options's ten largest holdings make up 44% of its $58.1M portfolio in Q2 2017.
  • FT Options opened 63 new positions and closed 151 in Q2 2017.
  • FT Options's portfolio value fell 24% quarter-over-quarter to $58.1M.

Based on FT Options's 13F filing for Q2 2017, filed 11 Aug 2017.